Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestiv ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual M ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual ...

syahrir maulana In my previous Aquestive Therapeutics (NASDAQ:AQST) article, I discussed how the company was approaching a significant milestone with the impending topline data readout for their Anaphylm (AQST-109) epinephrine sublingual film anticipated in Q1 of this year. At that time, the company had already initiated patient dosing in their Phase III pivotal study to evaluate Anaphylm’s pharmacokinetics (PK) and pharmacodynamics (PD) with the potential of a New Drug Application (NDA) filing in 2024. ...

Aquestive Therapeutics (AQST) ended the recent trading session at $4.14, demonstrating a +0.24% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.72%. Elsewhere, the Dow saw a downswing of 1%, while the tech-heavy Nasdaq depreciated by 0.95%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 1.2% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.The inv ...

Aquestive Therapeutics (AQST) closed the latest trading day at $4.38, indicating no change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.14% for the day. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq gained 0.17%.The the stock of specialty pharmaceutical company has risen by 66.54% in the past month, leading the Medical sector's gain of 0.88% and the S&P 500's gain of 5.34%.Investors will be eagerly watching for the performance of Aquestive T ...

Aquestive Therapeutics (NASDAQ:AQST) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares.Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering. There’s also a 30-day option for underwriters to acquire an additional 2.5 million shares at that same price.Aquestive Therapeutics is expecting $75 million in gross proceeds from the stock offering. The company will use these funds to continue the deve ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting disc ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of ...

Aquestive Therapeutics, Inc. (AQST) shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions. The stock price surge was also likely boosted by findings from the FDA Type C meeting.AQST’s Anaphylm is a non-invasive oral epinephrine product candidate. It has the potential to offer greater convenience of use compared with autoinjectors, ...